Shattuck Labs, Inc.

NASDAQ:STTK

Biotechnology

Healthcare
$4.47 +2.33%

+$0.11 today

Market cap
$455.24M
Beta
1.09
P/E (TTM)
-10.9
EPS (TTM)
-$0.44
52W Low $0.71High $8.33

Volume 2.08M

Average 0.69M

STTK Net Income

Bottom-line profit after all expenses, interest, and taxes.

Shattuck Labs, Inc.NASDAQ: STTK

Net Income · Q1 FY2026 · quarter ended Mar 2026

Net income remains negative

Q1 FY2026 net income was -$14.77M, compared with -$13.7M a year earlier. Trailing-twelve-month net income was -$49.87M.

Context

  • Net income amounted to 4880.9% of revenue in FY2025, up 3562.8 pp from a year earlier.
  • Net income grew in size in 0 of the last 3 fiscal years.
  • FY2025 was the smallest annual figure in the 4 fiscal years shown.

What to watch

Whether net income reaches the consensus estimate from 6 analysts of -$33.52M (+31.3%) for the fiscal year ending Dec 2026, a slowdown from the +35.3% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
-$14.77M-17.3% QoQ
Last fiscal yearDec 2025
-$48.81M+35.3% YoY
LTMMar 2026
-$49.87M+29.4% YoY
Net Income past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-7.8%-29.2%-21.5 pp
1 year+35.3%+31.3%-3.9 pp
3-year CAGR———
5-year CAGR——
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Net Income history

USD · from the income statement

Latest · FY2025
(48.81M) USD
Year-over-year change
+35.3%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Net Income vs competitors

How STTK compares with its peers on the latest reported figures

  • Peers report in different currencies, so net income is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +29.4% is the 3rd highest of 10, against a peer median of -35.9%.
  • Net income amounts to 4987.4% of revenue for STTK, versus a peer median of 58.2%.
STTK Competitors
Net Income for STTK and competitors
Company Period LTM YoY 3-year CAGR% of revenue
PBYIPuma Biotechnology, Inc.LTM Mar 2026$24.38M USD-35.9%+2396.3%10.7%
INDPIndaptus Therapeutics, Inc.LTM Mar 2026-$18.86M USD-19.7%——
NBPNovaBridge BiosciencesLTM Sep 2025-CN¥24.54M CNY+92.4%——
PDSBPDS Biotechnology CorporationLTM Mar 2026-$33.36M USD+6.0%——
SLSSELLAS Life Sciences Group, Inc.LTM Sep 2026-$35.76M USD-37.8%——
BDTXBlack Diamond Therapeutics, Inc.LTM Mar 2026-$43.21M USD-948.8%——
STTKShattuck Labs, Inc.LTM Mar 2026-$49.87M USD+29.4%—4987.4%
CBIOCrescent Biopharma, Inc.LTM Mar 2026-$162.08M USD-206.2%—1363.9%
FTHFaeth Therapeutics, Inc.LTM Jun 2026-$195.53M USD-629.0%——
IOVAIovance Biotherapeutics, Inc.LTM Sep 2026-$220.54M USD+44.5%—58.2%
Peer median (excluding STTK) —-35.9%+2396.3%58.2%

Competitors are the stored peer set for STTK. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue30.02M652K1.66M5.72M1M
Cost of Revenue1.38M82.2M4.04M4.89M0
Gross Profit28.64M(81.55M)(2.39M)827K1M
Gross Margin95.4%-12507.2%-143.9%14.5%100.0%
Research & Development56.56M82.9M74.31M67.21M35.27M
Selling, General & Admin18.72M19.68M19.3M19.08M17.24M
Operating Expenses73.91M21.78M89.57M81.39M52.51M
Depreciation & Amortization1.38M3.07M4.04M3.83M3.69M
EBITDA(43.59M)(98.87M)(83.26M)(71.58M)(45.12M)
EBITDA Margin-145.2%-15164.4%-5024.5%-1251.2%-4512.1%
Operating Income(45.27M)(103.33M)(91.96M)(80.57M)(51.51M)
Operating Margin-150.8%-15848.0%-5549.6%-1408.3%-5150.8%
Interest Income625K1.59M4.67M5.17M2.7M
Interest Expense00000
Other Income / Expenses295K1.38M4.66M5.16M2.7M
Income Before Tax(44.97M)(101.95M)(87.3M)(75.41M)(48.81M)
Pre-Tax Margin-149.8%-15635.7%-5268.4%-1318.1%-4880.9%
Income Tax Expense00000
Net Income(44.97M)(101.95M)(87.3M)(75.41M)(48.81M)
Net Margin-149.8%-15635.7%-5268.4%-1318.1%-4880.9%
EPS (Basic)(1.07)(2.41)(2.05)(1.49)(0.70)
EPS (Diluted)(1.07)(2.41)(2.05)(1.49)(0.70)
Weighted Avg Shares42.03M42.38M42.6M50.76M69.58M
Weighted Avg Shares (Diluted)42.03M42.38M42.6M50.76M69.58M

Shattuck Labs, Inc.

NASDAQ:STTK

Intrinsic Alpha fair value

Locked

Current Price

$4.47

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.